LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
2024 · Annals of Oncology · 34 citations
https://doi.org/10.1016/j.annonc.2024.08.2289